Publication & Citation Trends
Publications
0 total
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. OA
Cited by 59
Semantic Scholar
Ozanezumab Dose Selection for Amyotrophic Lateral Sclerosis by Pharmacokinetic-Pharmacodynamic Modelling of Immunohistochemistry Data from Patient Muscle Biopsies OA
Cited by 7
Semantic Scholar
Treatment with an antibody directed against Nogo-A delays disease progression in the SOD1G93A mouse model of Amyotrophic lateral sclerosis. OA
Cited by 43
Semantic Scholar
Mean plasma ozanezumab concentration-time profiles following single (A) or two (B) IV infusions of ozanezumab. OA
Cited by 0
Semantic Scholar
Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study OA
Cited by 2
Semantic Scholar
Programme for the 112th Meeting of the British Neuropathological Society, Institute of Child Health, London, UK, 5–7 January 2011
Cited by 0
Semantic Scholar
Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy OA
Cited by 71
Semantic Scholar
Research Topics
Cancer-related Molecular Pathways
(19)
Cancer Research and Treatments
(8)
Cell death mechanisms and regulation
(4)
Ubiquitin and proteasome pathways
(4)
Epigenetics and DNA Methylation
(3)
Affiliations
The Honourable Society of Lincoln's Inn
Genesis Laboratories
Cancer Research Center
Frederick National Laboratory for Cancer Research
National Cancer Institute